Filing identity and reporting period
Important discrepancy: The request identifies TALPHERA, INC., but the supplied Form 10-Q is for AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX). This summary reflects the filing text provided and should not be attributed to Talphera without verifying the source. The filing covers the quarter ended March 31, 2020; financial statements are unaudited.
AcelRx develops and commercializes therapies for acute pain in medically supervised settings. Its portfolio includes U.S.-marketed DSUVIA, European DZUVEO, and Zalviso, which is marketed in Europe by Grünenthal and remains in development for U.S. approval.
Financial performance and condition
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Total revenue | $0.386 million | $0.265 million; up 46% |
| Product sales | $0.274 million | $0.126 million; up 117% |
| Net loss | $15.925 million | $13.674 million |
| Net loss per share | $0.20 | $0.17 |
| Operating cash used | $14.364 million | $13.240 million |
- DSUVIA sales were $0.155 million, versus $0.047 million; Zalviso sales were $0.119 million, versus $0.079 million. Collaboration and other revenue declined to $0.112 million from $0.139 million.
- Cost of goods sold was $1.511 million against revenue of $0.386 million, implying a gross loss of about $1.125 million and a gross margin of approximately negative 291%. Management expects negative gross margins on Zalviso supplied to Grünenthal at current volumes and transfer prices.
- Operating expenses were $16.234 million, up from $12.583 million. SG&A rose 33% to $13.311 million, including $1.8 million in Tetraphase acquisition costs and higher personnel expense. R&D was broadly flat at $1.412 million.
- Interest expense was $0.855 million. Other expense totaled $0.077 million, compared with $1.356 million in Q1 2019; the comparison was affected by non-cash interest on the royalty-monetization liability.
- Cash, cash equivalents and short-term investments were $52.725 million at quarter-end, down from $66.137 million at December 31, 2019. Current assets were $58.045 million and current liabilities $15.721 million.
- Balance-sheet long-term debt was $25.744 million, including current and non-current portions; management reported an accrued Oxford loan balance of $24.5 million. The separate liability related to sale of future royalties was $91.113 million. Stockholders’ deficit was $55.281 million.
- Cash from investing activities was $22.650 million, mainly reflecting maturities of investments; financing activities provided $0.916 million, including $0.784 million of ATM equity proceeds. The increase in cash should not be confused with operating cash generation, which remained negative.
Material changes and significant developments
- Product sales increased as the DSUVIA U.S. launch progressed and Grünenthal placed larger Zalviso orders, but total losses and operating cash use increased year over year.
- On March 15, 2020, AcelRx agreed to acquire Tetraphase in a stock-and-contingent-value-right transaction. AcelRx estimated its shareholders would own about 85.4% of the combined company and Tetraphase securityholders about 14.6%. The merger remained subject to closing conditions.
- After quarter-end, Tetraphase disclosed a competing La Jolla proposal of $22 million in cash plus up to $12.5 million under contingent value rights. Tetraphase’s board said it would consider the proposal while continuing to recommend the AcelRx merger as of May 8, 2020.
- Ten lawsuits had been filed by alleged Tetraphase stockholders challenging merger disclosures or process. The company said it could not estimate a potential loss and accrued no amount.
- AcelRx eliminated 30 positions, primarily in the commercial organization, in connection with a co-promotion arrangement with Tetraphase; it recorded $0.5 million in termination benefits. The reduction was completed in Q1, with no additional plan costs anticipated.
- In April 2020, DSUVIA received Department of Defense Milestone C approval, clearing the path for DoD orders.
Outlook, risks and unusual items
- Management said existing capital resources were expected to fund operations through Q2 2021, subject to uncertainties including COVID-19, DSUVIA sales, merger-related spending and commercial-launch costs. It also stated that longer-term operations would require additional capital.
- COVID-19 restrictions curtailed sales and medical-affairs access to hospitals and surgery centers and reduced promotional activity. Management expected near-term sales volumes to be adversely affected while access remained restricted; reduced travel and promotional activity could also lower expenses.
- A Zalviso supplier issued a force majeure notice, and AcelRx issued one to Grünenthal. Management did not then expect a significant financial impact but warned that prolonged disruption could affect supply and sales. COVID-related travel restrictions delayed packaging-line testing and acceptance; installation was projected for 2020 and qualification for 2021. Management expected the line to reduce cost of goods sold beginning in 2022.
- The company expects continued operating losses and negative operating cash flows until DSUVIA achieves market acceptance and generates significant revenue. Zalviso U.S. NDA resubmission timing depended in part on FDA opioid guidance; approval, timing and commercial prospects remained uncertain.
- The royalty monetization liability reflects payments to PDL from specified European royalties and milestones. A prior estimate revision led management to estimate approximately $20 million of future payments and a possible contingent gain of approximately $45 million at the end of the arrangement; realization, amount and timing are uncertain. Management anticipated about $3 million of non-cash interest income from the arrangement in 2020.
- Key risks include the uncertain Tetraphase transaction and integration, COVID-related sales and supply disruption, dependence on third-party manufacturing and a limited API supply base, opioid regulation and safety/REMS requirements, negative product margins, and the need for additional financing. The Oxford loan also includes restrictive covenants and a $5 million minimum unrestricted-cash requirement.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is AcelRx’s, not Talphera’s, and verify the correct company and filing before relying on these figures.
- Check the status and final terms of the Tetraphase merger, the La Jolla proposal, related litigation and any resulting dilution or transaction costs.
- Assess cash runway against ongoing operating cash burn, Oxford debt obligations, merger spending, and the availability and potential dilution from the remaining $44.5 million ATM capacity.
- Track DSUVIA sales, hospital access, DoD orders, COVID-related effects, and whether the packaging line is installed and qualified on schedule.
- Verify Zalviso regulatory progress, Grünenthal demand and supply continuity, and whether manufacturing cost reductions can address negative gross margins.
- Monitor the assumptions underlying the possible PDL contingent gain; it is uncertain and is not equivalent to current cash or assured income.